000205: PROGNOSTIC FACTORS AND SURVIVAL RATE IN PATIENTS WITH EPITHELIAL OVARIAN CANCER TREATED WITH PACLITAXEL AND CARBOPLATIN

Objectives: The purpose of this retrospective study is to identify prognostic factors and survival rate in patients with epithelial ovarian cancer treated with combination chemotherapy. Methods: Carboplatin and Cyclophosphamide were used in stage Ic and Paclitaxel and Carboplatin were used in stabe II to IV after primary Surgery. Results: FIGO stage distribution of 98 patients were 38.2% for stage, 5.9% for stage a, 44.1% for stage b, 11.8% for stage %. The histopathologic type distribution were serous type (45.6%), mucinous type (36.8%), endometriod type (8.8%), clear cell type (7.4%), mixed type (1.4%). In 18 patients (26.5%, residual tumor size more than 1 cm after primary cytoreductive surgery. The overall 5-year survival rate was 55.7%, and 5-year survival rate of each stage were as follow: 95.8% (stage I&II), 28.4% (stage b), 0% (stage v). The overall survival time of stage/a were 90 months, stage b 39 months, stage v 17 months. In multivariate analysis of prognostic factors, P value of FIGO stage, residual tumor volume, and ascitic fluid volume were calculated as follow p = 0.011, p = 0.026, p = 0.031. Conclusions: Paclitaxel and Carboplatin were effective chemotherapeutic agents in stage II to IV serous ovarian cancert patients. FIGO stage, residual volume, ascitic fluid volume were most significant independent prognostic factors.